Rituximab can induce remission of nephrotic syndrome in the absence of peripheral B‐cells
暂无分享,去创建一个
[1] M. Gos,et al. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. , 2014, Developmental period medicine.
[2] J. Deegens,et al. B cell suppression in primary glomerular disease. , 2014, Advances in chronic kidney disease.
[3] H. Koenen,et al. A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[4] T. Mochizuki,et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] V. Vega-Warner,et al. Focal segmental glomerulosclerosis in association with neurofibromatosis type 1: a case report and proposed molecular pathways , 2013, Clinical kidney journal.
[6] Mei-Mei Cheng,et al. Minimal Change Disease in a Patient with Neurofibromatosis Type I , 2012 .
[7] M. Rastaldi,et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.
[8] Steven Z. Athanases,et al. Clinical and genetic aspects of neurofibromatosis 1 , 2010, Genetics in Medicine.
[9] F. McCormick,et al. Ras regulation. NF is enough of GAP. , 1992, Nature.